Compugen Ltd. (NASDAQ: CGEN) has never declared or paid cash dividends on its common stock since its public market inception. As a clinical-stage biotechnology and computational drug discovery enterprise, the company consistently retains all available capital and earnings to fund intensive research and development programs, preclinical pipelines, clinical trials, and operational expansion rather than distributing cash yields to shareholders.